Research contextSee what supports this page, how current it is, and where comparable or historical context is available.
- Research date
- Sep 21, 2026Use the dated article and cited sources for the definition, examples, and stated limitations.
- Operating-model context
- 16 connected conceptsPart of the reviewed Biopharma Development and Commercialization; issuer definitions remain distinct where disclosed.
Patient enrollment measures the number of participants targeted or actually enrolled in a clinical study.
ClinicalTrials.gov defines enrollment as the estimated target number or actual total number of participants enrolled. Screening alone does not necessarily count as enrollment.
Why enrollment matters
Enrollment pace can affect:
- trial completion timing;
- data-readout timing;
- clinical spending;
- competitive positioning; and
- the risk of protocol changes.
A sponsor can have a scientifically promising study but still face delays if recruitment is slower than expected.
Investor interpretation
Look for:
- target enrollment;
- actual enrollment;
- number of active sites;
- geographic expansion;
- inclusion and exclusion criteria;
- disease prevalence; and
- competing trials recruiting the same patients.
Source:
Enrollment is a trial-execution measure, not evidence that the treatment is effective.
Part of the Biopharma Development and Commercialization
Connect clinical-trial evidence, FDA application and expedited pathways, collaboration economics, gross-to-net commercialization, and loss-of-exclusivity risk to understand drug-development businesses.
How the model fits together
- Clinical evidence and execution: Trial phase frames development maturity, enrollment affects execution timing, primary and secondary endpoints define the prespecified evidence hierarchy, and a readout converts that study design into new evidence for investors to interpret.
- FDA pathway and review milestones: NDA and BLA submissions begin formal marketing review for drugs and biologics, PDUFA dates frame target action timing, and accelerated approval, Breakthrough Therapy, and Orphan Drug designations describe distinct regulatory pathways or incentives rather than approval outcomes.
- Commercialization, partnerships, and exclusivity: Gross-to-net adjustments bridge gross product demand to recognized revenue, royalties and milestones describe partner economics, and patent expiry plus loss of exclusivity frame when legal protection may translate into competitive revenue erosion.
Continue Research
Continue from the concept into the Grizzly Bulls research surface that best matches the next question. These links are research continuations, not recommendations or required steps.
Compare stocks
Compare biopharma stocks
Continue into stock comparison for pipeline stage, regulatory milestones, commercialization economics, concentration, and valuation context.
Explore more topics in the Financial Research Encyclopedia.